<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR) against human carcinoembryonic antigen (CEA) were administered to three patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> refractory to standard treatments </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients experienced profound decreases in serum CEA levels (74-99%), and one patient had an objective regression of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> metastatic to the lung and liver </plain></SENT>
<SENT sid="2" pm="."><plain>However, a severe transient inflammatory <z:hpo ids='HP_0002583'>colitis</z:hpo> that represented a dose limiting toxicity was induced in <z:hpo ids='HP_0000001'>all</z:hpo> three patients </plain></SENT>
<SENT sid="3" pm="."><plain>This report represents the first example of objective regression of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> mediated by adoptive T cell transfer and illustrates the successful use of a TCR, raised in human leukocyte antigen (HLA) transgenic mice, against a human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> associated antigen </plain></SENT>
<SENT sid="4" pm="."><plain>It also emphasizes the destructive power of small numbers of highly <z:chebi fb="156" ids="39214">avid</z:chebi> T cells and the limitations of using CEA as a target for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy </plain></SENT>
</text></document>